Publications by authors named "Teodora Perger"

Claim this Profile
I
Impact of HIV-Related Stigma on Antiretroviral Therapy Adherence, Engagement and Retention in HIV Care, and Transition to Adult HIV Care in Pediatric and Young Adult Populations Living With HIV: A Literature Review.
Teodora Perger, Mariam Davtyan, Caroline Foster, Michael Evangeli, Claire Berman

AIDS Behav· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.
Lisa L Ross, A Sarah Walker, Yu Lou, Allan R Tenorio, Diana M Gibb, Teodora Perger

PLoS One· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure.
Chris M Stainsby, Teodora M Perger, Vani Vannappagari, Karam C Mounzer, Ricky K Hsu

Pharmacotherapy· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials.
Cassandra Nan, Mark Shaefer, Rimgaile Urbaityte, James Oyee, Judy Hopking, Teodora Perger

Open Forum Infect Dis· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open-Label, Randomized Study.
Kimberly Adkison, Allen Wolstenholme, Yu Lou, Zhiping Zhang, Amy Eld, Teodora Perger

Clin Pharmacol Ther· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data.
Mark Cotton, Haseena Cassim, Noris Pavía-Ruz, Harmony P Garges, Teodora Perger

Pediatr Infect Dis J· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.
Claudia Fortuny, Dan Duiculescu, Katharine Cheng, Harmony P Garges, Mark Cotton, Teodora Perger

Pediatr Infect Dis J· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis